

# Scott J Rodig

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8024679/publications.pdf>

Version: 2024-02-01

235  
papers

27,894  
citations

13865

67  
h-index

6131

159  
g-index

241  
all docs

241  
docs citations

241  
times ranked

34778  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 311-319.	27.0	3,099
2	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221.	27.8	2,112
3	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	30.7	1,224
4	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016, 7, 10501.	12.8	1,163
5	Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. <i>Nature Immunology</i> , 2019, 20, 326-336.	14.5	1,148
6	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2010, 116, 3268-3277.	1.4	1,122
7	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	27.8	956
8	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2698-2704.	1.6	868
9	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 1283-1294.	10.7	818
10	Unique Clinicopathologic Features Characterize <i>ALK</i> -Rearranged Lung Adenocarcinoma in the Western Population. <i>Clinical Cancer Research</i> , 2009, 15, 5216-5223.	7.0	645
11	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2013, 24, 777-790.	16.8	635
12	<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.	1.6	634
13	Association of Polymerase $\epsilon$ Mutated and Microsatellite-Unstable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. <i>JAMA Oncology</i> , 2015, 1, 1319.	7.1	523
14	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13587-13598.	1.8	485
15	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	16.8	475
16	Immunological mechanisms of the antitumor effects of supplemental oxygenation. <i>Science Translational Medicine</i> , 2015, 7, 277ra30.	12.4	458
17	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	21.4	438
18	Targetable genetic features of primary testicular and primary central nervous system lymphomas. <i>Blood</i> , 2016, 127, 869-881.	1.4	429

#	ARTICLE	IF	CITATIONS
19	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	425
20	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	10.3	416
21	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204.	14.3	400
22	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. <i>Cancer Immunology Research</i> , 2016, 4, 124-135.	3.4	339
23	The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo. <i>Cell</i> , 2015, 161, 319-332.	28.9	293
24	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	5.5	278
25	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	1.6	273
26	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 2420-2430.	1.4	262
27	Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. <i>Oncotarget</i> , 2016, 7, 32925-32932.	1.8	248
28	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , 2021, 27, 515-525.	30.7	248
29	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	1.6	216
30	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. <i>Nature Medicine</i> , 2018, 24, 1143-1150.	30.7	212
31	Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1563.	7.1	198
32	Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems. <i>Science</i> , 2021, 371, .	12.6	197
33	Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2012, 22, 359-372.	16.8	179
34	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. <i>Nature Communications</i> , 2020, 11, 1459.	12.8	176
35	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	4.1	170
36	Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Related Head and Neck Cancer: A Multicenter, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5140-5152.	7.0	163

#	ARTICLE	IF	CITATIONS
37	Classical Hodgkin Lymphoma with Reduced $\hat{I}^2$ M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , 2016, 4, 910-916.	3.4	146
38	Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1715-1723.	3.7	138
39	Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H). <i>Clinical Cancer Research</i> , 2006, 12, 7174-7179.	7.0	133
40	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019, 134, 22-29.	1.4	129
41	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1123-1129.	3.4	127
42	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 66-82.	13.2	126
43	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. <i>JAMA Oncology</i> , 2016, 2, 518.	7.1	121
44	Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. <i>Blood</i> , 2018, 132, 825-836.	1.4	121
45	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 279-291.	10.7	118
46	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
47	Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2014, 20, 2674-2683.	7.0	114
48	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1308-1315.	3.4	114
49	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq1 1 0.784314 rgBT /Overlo 1.6 110		
50	Mutations in G protein $\hat{I}^2$ subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015, 21, 71-75.	30.7	106
51	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 1524-1541.	9.4	103
52	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. <i>Blood</i> , 2018, 132, 1495-1506.	1.4	100
53	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. <i>Blood Advances</i> , 2019, 3, 4065-4080.	5.2	99
54	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2851-2860.	7.0	96

#	ARTICLE	IF	CITATIONS
55	Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 29-41.	16.8	95
56	Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. <i>Blood</i> , 2014, 124, 291-291.	1.4	92
57	Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. <i>Blood Advances</i> , 2017, 1, 2643-2654.	5.2	91
58	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , 2020, 26, 1468-1479.	30.7	87
59	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021, 11, 1952-1969.	9.4	87
60	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. <i>Oncology</i> , 2017, 6, e1277308.	4.6	84
61	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. <i>Blood</i> , 2021, 138, 1081-1085.	1.4	84
62	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	3.4	81
63	Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 106-112.	3.7	77
64	The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4644-4655.	7.0	76
65	Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1477-90.	2.3	75
66	BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. <i>Human Pathology</i> , 2005, 36, 1113-1119.	2.0	74
67	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. <i>Blood</i> , 2018, 132, 92-92.	1.4	74
68	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 858-868.	3.4	73
69	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. <i>Blood</i> , 2019, 134, 2369-2382.	1.4	72
70	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	27.8	70
71	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. <i>Blood</i> , 2016, 127, 2203-2213.	1.4	68
72	AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features. <i>Clinical Cancer Research</i> , 2008, 14, 3338-3344.	7.0	67

#	ARTICLE	IF	CITATIONS
73	An Oncogenic Role for Alternative NF- $\kappa$ B Signaling in DLBCL Revealed upon Deregulated BCL6 Expression. <i>Cell Reports</i> , 2015, 11, 715-726.	6.4	66
74	The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative. <i>Blood</i> , 2019, 134, 2059-2069.	1.4	66
75	Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. <i>Cell Death and Differentiation</i> , 2017, 24, 251-262.	11.2	65
76	Aggressive Langerhans cell histiocytosis following T $\alpha$ ALL: Clonally related neoplasms with persistent expression of constitutively active NOTCH1. <i>American Journal of Hematology</i> , 2008, 83, 116-121.	4.1	63
77	Characterization of the Neuroendocrine Tumor Immune Microenvironment. <i>Pancreas</i> , 2018, 47, 1123-1129.	1.1	63
78	Cytotoxic T Cells in PD-L1 $\alpha$ Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016, 4, 1038-1048.	3.4	62
79	Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6012-6012.	1.6	62
80	IL-12 gene-deficient C57BL / 6 mice are susceptible to <i>Leishmania donovani</i> but have diminished hepatic immunopathology. <i>European Journal of Immunology</i> , 2000, 30, 834-839.	2.9	61
81	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with <i>JAK3</i> Activation. <i>Cancer Immunology Research</i> , 2015, 3, 855-863.	3.4	60
82	Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair $\alpha$ Deficient Colorectal Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1230-1236.	3.4	59
83	A Zebrafish Model of Myelodysplastic Syndrome Produced through <i>tet2</i> Genomic Editing. <i>Molecular and Cellular Biology</i> , 2015, 35, 789-804.	2.3	58
84	Characteristic Expression Patterns of TCL1, CD38, and CD44 Identify Aggressive Lymphomas Harboring a MYC Translocation. <i>American Journal of Surgical Pathology</i> , 2008, 32, 113-122.	3.7	53
85	A phase I trial of panobinostat ( <i>LBH589</i> ) in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 3041-3050.	2.8	51
86	Targetable genetic alterations of <i>TCF4</i> ( <i>E2-2</i> ) drive immunoglobulin expression in diffuse large B cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	51
87	Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. <i>Cancer Discovery</i> , 2020, 10, 1296-1311.	9.4	49
88	SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1176-1187.	1.1	49
89	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel. <i>Blood</i> , 2019, 134, 203-203.	1.4	48
90	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	48

#	ARTICLE	IF	CITATIONS
91	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 841-850.	2.5	47
92	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 122-126.	5.2	46
93	TRAF1 Expression and c-Rel Activation Are Useful Adjuncts in Distinguishing Classical Hodgkin Lymphoma From a Subset of Morphologically or Immunophenotypically Similar Lymphomas. <i>American Journal of Surgical Pathology</i> , 2005, 29, 196-203.	3.7	45
94	Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. , 2021, 9, e003536.		45
95	Combined protein and nucleic acid imaging reveals virus-dependent B cell and macrophage immunosuppression of tissue microenvironments. <i>Immunity</i> , 2022, 55, 1118-1134.e8.	14.3	44
96	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	3.5	43
97	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 1046-1055.	3.4	42
98	HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. <i>Blood</i> , 2016, 128, 2517-2526.	1.4	37
99	MITI minimum information guidelines for highly multiplexed tissue images. <i>Nature Methods</i> , 2022, 19, 262-267.	19.0	37
100	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. <i>Journal of Translational Medicine</i> , 2015, 13, 294.	4.4	36
101	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1110-1110.	1.4	35
102	The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative disorders. <i>Human Pathology</i> , 2005, 36, 51-57.	2.0	31
103	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2016, 2, 16002.	5.2	31
104	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520.	2.0	31
105	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1353-1364.	1.4	31
106	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. <i>Onc Immunology</i> , 2018, 7, e1440930.	4.6	30
107	MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. <i>American Journal of Clinical Pathology</i> , 2016, 145, 166-179.	0.7	29
108	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. <i>Haematologica</i> , 2010, 95, 2056-2062.	3.5	28



#	ARTICLE	IF	CITATIONS
109	Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 19-30.	2.8	25
110	High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. <i>Modern Pathology</i> , 2014, 27, 1447-1454.	5.5	24
111	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 137-145.	0.8	24
112	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. <i>Haematologica</i> , 2020, 105, 1361-1368.	3.5	23
113	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 62.	5.4	23
114	Overview of Tissue Imaging Methods. <i>Methods in Molecular Biology</i> , 2020, 2055, 455-465.	0.9	23
115	Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 25575-25587.	1.8	20
116	Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative disorders. <i>Cancer Genetics and Cytogenetics</i> , 2006, 171, 44-51.	1.0	18
117	Disruption of <i>asxl1</i> results in myeloproliferative neoplasms in zebrafish. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	18
118	RelA-Induced Interferon Response Negatively Regulates Proliferation. <i>PLoS ONE</i> , 2015, 10, e0140243.	2.5	16
119	Surface Light Chain Expression in Primary Mediastinal Large B-Cell Lymphomas by Multiparameter Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 2015, 144, 635-641.	0.7	16
120	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 313-341.	22.4	15
121	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019, 24, 1013-1021.	3.7	15
122	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. <i>Blood</i> , 2013, 122, 2823-2823.	1.4	15
123	Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2009, 114, 4785-4785.	1.4	14
124	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. <i>Laboratory Investigation</i> , 2017, 97, 207-216.	3.7	13
125	Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML. <i>Blood</i> , 2016, 128, 1340-1340.	1.4	12
126	Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11007-11007.	1.6	11



#	ARTICLE	IF	CITATIONS
127	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	3.0	11
128	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clinical Cancer Research, 2021, 27, 5072-5083.	7.0	10
129	Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. Blood, 2014, 124, 289-289.	1.4	10
130	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Research Communications, 2021, 1, 30-40.	1.7	10
131	Impact of Operator Techniques On Quality of Bone Marrow Assessment. Blood, 2012, 120, 2055-2055.	1.4	10
132	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
133	Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. Journal of Clinical Investigation, 2022, 132, .	8.2	10
134	Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 1196-1206.	3.0	9
135	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. Modern Pathology, 2020, 33, 1380-1388.	5.5	9
136	Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis.. Journal of Clinical Oncology, 2016, 34, 5514-5514.	1.6	9
137	Clinical and Biological Evaluation of the Novel CD30/CD16A Tetraivalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202). Blood, 2018, 132, 2908-2908.	1.4	8
138	A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas. Blood, 2011, 118, 261-261.	1.4	8
139	Phase I study of sapacitabine and seliciclib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2503-2503.	1.6	8
140	Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)â€™A phase 2 study.. Journal of Clinical Oncology, 2016, 34, 7535-7535.	1.6	8
141	Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.. Journal of Clinical Oncology, 2019, 37, 49-49.	1.6	8
142	Tumor infiltrating and peritumoral T cells and expression of PD-L1 in BRCA1/2-mutated high grade serous ovarian cancers.. Journal of Clinical Oncology, 2015, 33, 5512-5512.	1.6	7
143	Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine.. Journal of Clinical Oncology, 2018, 36, 2020-2020.	1.6	7
144	Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. , 2021, 9, e003318.		7

#	ARTICLE	IF	CITATIONS
145	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. <i>Blood Advances</i> , 2016, 1, 84-92.	5.2	6
146	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. <i>Blood</i> , 2012, 120, 1545-1545.	1.4	6
147	A Simple and Effective Method for Flow Cytometric Study of Lymphoid Malignancies Using Needle Core Biopsy Specimens. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 793-799.	1.5	5
148	Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetraivalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202). <i>Blood</i> , 2020, 136, 25-26.	1.4	5
149	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. <i>Blood</i> , 2010, 116, 990-990.	1.4	5
150	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016, 128, 2923-2923.	1.4	5
151	Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy. <i>Blood</i> , 2015, 126, 817-817.	1.4	5
152	Nodular primary cutaneous melanoma is associated with PD-L1 expression. <i>European Journal of Dermatology</i> , 2020, 30, 352-357.	0.6	4
153	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9018-9018.	1.6	4
154	IL-12 gene-deficient C57BL/6 mice are susceptible to <i>Leishmania donovani</i> but have diminished hepatic immunopathology. , 2000, 30, 834.		4
155	Comprehensive Genomic Analysis of Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1564-1564.	1.4	4
156	Quantitative Assessment of PD-L1 Expression in Classical Hodgkin Lymphoma Suggests a Critical Role for Tumor Associated Macrophages in Suppressing Anti-Tumor Immunity. <i>Blood</i> , 2015, 126, 1440-1440.	1.4	4
157	In Silico and Functional Characterization of TBL1XR1 as a Tumor Suppressor in Large B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 612-612.	1.4	4
158	Response and oligoclonal resistance to pembrolizumab in uterine leiomyosarcoma: Genomic, neoantigen, and immunohistochemical evaluation.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11043-11043.	1.6	4
159	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , 2015, 126, 176-176.	1.4	4
160	First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2009-2009.	1.6	3
161	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 706-706.	1.4	3
162	Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 3663-3663.	1.4	3

#	ARTICLE	IF	CITATIONS
163	GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition. <i>Blood</i> , 2014, 124, 3567-3567.	1.4	3
164	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	1.4	3
165	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	1.4	3
166	Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2084-2084.	1.6	3
167	Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5511-5511.	1.6	3
168	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	1.4	3
169	Use of Fluoro- <sup>18</sup> F-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, 148, 268.	2.2	3
170	Three-year outcomes and correlative analyses in patients with non-small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9043-9043.	1.6	3
171	P2RY8-CRLF2 Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy. <i>JCO Precision Oncology</i> , 2020, 4, 152-160.	3.0	2
172	Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9121-9121.	1.6	2
173	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 1650-1650.	1.4	2
174	Comprehensive Genomic Analysis of Flow-Sorted Hodgkin Reed Sternberg Cells Reveals Additional Genetic Bases of Immune Evasion. <i>Blood</i> , 2018, 132, 1559-1559.	1.4	2
175	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1579-1579.	1.4	2
176	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 2997-2997.	1.4	2
177	Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , 2011, 118, 2912-2912.	1.4	2
178	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011, 118, 3966-3966.	1.4	2
179	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. <i>Blood</i> , 2014, 124, 74-74.	1.4	2
180	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3156-3156.	1.4	2

#	ARTICLE	IF	CITATIONS
181	Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1005-1005.	1.6	2
182	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. Blood, 2011, 118, 1405-1405.	1.4	2
183	655â€¦Landscape of helper and regulatory CD4+ T cells in melanoma. , 2021, 9, A684-A684.		2
184	Editorial: Defining the Spatial Organization of Immune Responses to Cancer and Viruses In Situ. Frontiers in Immunology, 2022, 13, 847582.	4.8	2
185	A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and <i>CDK12</i>-loss metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, TPS213-TPS213.	1.6	2
186	Abstract P1-04-05: Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer. Cancer Research, 2022, 82, P1-04-05-P1-04-05.	0.9	2
187	Duration of symptoms does not correlate with results of Tâ€cell gene rearrangement studies in patients evaluated for cutaneous Tâ€cell lymphoma. Journal of Cutaneous Pathology, 2015, 42, 618-621.	1.3	1
188	Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.. Journal of Clinical Oncology, 2021, 39, 9567-9567.	1.6	1
189	Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. Oncogene, 2021, 40, 5718-5729.	5.9	1
190	Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 3021-3021.	1.4	1
191	Preclinical Analyses Of The Chemical JAK2 Inhibitor, SAR302503, In Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. Blood, 2013, 122, 4230-4230.	1.4	1
192	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 631-631.	1.4	1
193	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2686-2686.	1.4	1
194	Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).. Journal of Clinical Oncology, 2016, 34, 6052-6052.	1.6	1
195	CIMAC-CIDC tissue imaging harmonization.. Journal of Clinical Oncology, 2020, 38, 3125-3125.	1.6	1
196	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. Blood, 2010, 116, 1042-1042.	1.4	1
197	Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma. Blood, 2011, 118, 2908-2908.	1.4	1
198	Phase I study of sequential sapacitabine and seliciclib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3053-3053.	1.6	1

#	ARTICLE	IF	CITATIONS
199	BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 672-672.	1.4	1
200	Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9515-9515.	1.6	1
201	T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. <i>Blood</i> , 2019, 134, 680-680.	1.4	1
202	374â€¦A phase IB trial of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2021, 9, A402-A404.		1
203	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2022, 40, 549-549.	1.6	1
204	Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9021-9021.	1.6	1
205	Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after surgical resection.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8514-8514.	1.6	1
206	Reply to Z. Wu et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2657-2657.	1.6	0
207	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi8-vi8.	1.2	0
208	Is radiation necrosis in radiated melanoma brain metastasis increasing because immunotherapy is contributing to this or are patients just living longer?. <i>Journal of Clinical Oncology</i> , 2021, 39, e21518-e21518.	1.6	0
209	Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9119-9119.	1.6	0
210	Abstract 26: Association of aneuploidy score with clinical outcomes to immunotherapy in NSCLC. , 2021, , .		0
211	Expression and Targeted Inhibition of the Immunoregulatory Carbohydrate-Binding Lectin, Galectin 1, in EBV-Driven Post-Transplant Lymphoproliferative Disorders.. <i>Blood</i> , 2009, 114, 96-96.	1.4	0
212	Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application.. <i>Blood</i> , 2009, 114, 1841-1841.	1.4	0
213	Mir-15a/16-1 Cluster Is Frequently Deleted In Primary Hodgkin Lymphoma and Modulates Multiple Survival Pathways Including AP-1. <i>Blood</i> , 2010, 116, 746-746.	1.4	0
214	Integrative Analysis Reveals Multiple Alterations of p53 Signaling Pathway Components In Primary Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2010, 116, 635-635.	1.4	0
215	Kruppel-Like Factor 10 (KLF10)-Deficient Mice Have Marked Defects In EPC Differentiation, Function, and Angiogenesis. <i>Blood</i> , 2010, 116, 4314-4314.	1.4	0
216	Biology and Therapeutic Targeting of Sp1 Transactivation In Myeloma. <i>Blood</i> , 2010, 116, 134-134.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma. Blood, 2010, 116, 4042-4042.	1.4	0
218	Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,. Blood, 2011, 118, 3671-3671.	1.4	0
219	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1534-1534.	1.4	0
220	A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma: Association Between Advanced Age and Mutations in TET2 and DNMT3A. Blood, 2012, 120, 299-299.	1.4	0
221	Abstract B067: Taxonomy of breast cancer based on normal cell phenotype and ontology. , 2013, , .		0
222	Targeting Oncogenic Interleukin-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2535-2535.	1.4	0
223	Alterations In Mitochondrial Priming May Be a Mechanism For Acquired Resistance To Therapy In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 1764-1764.	1.4	0
224	Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. Blood, 2014, 124, 3961-3961.	1.4	0
225	Resolving the Biological Heterogeneity of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between DLBCL and BL (BCL-U) Using Quantitative Profiles of Oncogenic Signaling Networks. Blood, 2015, 126, 3903-3903.	1.4	0
226	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3922-3922.	1.4	0
227	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. Blood, 2015, 126, 2655-2655.	1.4	0
228	Immune biomarkers and treatment (tx) outcome in hormone receptor-positive (HR+) breast cancer (BC) patients (pts) treated with preoperative chemotherapy (preop chemo) plus bevacizumab (bev).. Journal of Clinical Oncology, 2017, 35, e12134-e12134.	1.6	0
229	The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): Relationship to non-metastatic (met) tumors and prior treatment (tx) received.. Journal of Clinical Oncology, 2018, 36, 1054-1054.	1.6	0
230	Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade. Blood, 2019, 134, 1493-1493.	1.4	0
231	67â€¦Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer. , 2021, 9, A74-A75.		0
232	700â€¦Increasing MHC-I expression to potentiate immune checkpoint blockade therapy. , 2021, 9, A728-A728.		0
233	Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 713-713.	1.4	0
234	Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (â‰¥ 50%) nonâ€¦small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9054-9054.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.. Journal of Clinical Oncology, 2022, 40, 2616-2616.	1.6	0